Walgreens Sells Another Stake In Distributor Cencora For $300 Million
Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said Thursday night.
COR Stock Gains on Q1 Earnings & Revenue Beat & Upbeat '25 Outlook
COR's first-quarter fiscal 2025 results showcase a strong segmental performance. The company's sales and earnings guidance for fiscal 2025 looks encouraging.
Cencora (COR) Q1 2025 Earnings Call Transcript
Cencora Inc. (NYSE:COR ) Q1 2025 Earnings Conference Call February 5, 2025 8:30 AM ET Company Participants Robert Mauch - President, Chief Executive Officer James Cleary - Executive Vice President, Chief Financial Officer Bennett Murphy - Senior Vice President, Head of Investor Relations Conference Call Participants Michael Cherny - Leerink Partners Lisa Gill - JP Morgan Elizabeth Anderson - Evercore ISI Steven Valiquette - Mizuho Securities Eric Percher - Nephron Research Daniel Grosslight - Citi Stephen Baxter - Wells Fargo Charles Rhyee - TD Cowen Allen Lutz - Bank of America George Hill - Deutsche Bank Erin Wright - Morgan Stanley Kevin Caliendo - UBS Eric Coldwell - Baird Operator Hello and welcome everyone to the Cencora Q1 fiscal year 2025 earnings call. My name is Becky and I'll be your Operator today.
Here's What Key Metrics Tell Us About Cencora (COR) Q1 Earnings
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cencora (COR) Surpasses Q1 Earnings and Revenue Estimates
Cencora (COR) came out with quarterly earnings of $3.73 per share, beating the Zacks Consensus Estimate of $3.50 per share. This compares to earnings of $3.28 per share a year ago.
Cencora raises 2025 profit forecast on specialty drug demand
Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.
Why Cencora (COR) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Stay Ahead of the Game With Cencora (COR) Q1 Earnings: Wall Street's Insights on Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Cencora to Report Q1 Earnings: Is a Beat Likely for the Stock?
COR's fiscal first-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Cencora (COR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
